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Abstract
Background: Although age, obesity and pre-existing chronic diseases are established risk factors for COVID-19
outcomes, their interactions have not been well researched.
Methods: We used data from the Clinical Characterisation Protocol UK (CCP-UK) for Severe Emerging Infection
developed by the International Severe Acute Respiratory and emerging Infections Consortium (ISARIC). Patients
admitted to hospital with COVID-19 from 6th February to 12th October 2020 were included where there was a
coded outcome following hospital admission. Obesity was determined by an assessment from a clinician and
chronic disease by medical records. Chronic diseases included: chronic cardiac disease, hypertension, chronic kidney
disease, chronic pulmonary disease, diabetes and cancer. Mutually exclusive categories of obesity, with or without
chronic disease, were created. Associations with in-hospital mortality were examined across sex and age categories.
Results: The analysis included 27,624 women with 6407 (23.2%) in-hospital deaths and 35,065 men with 10,001
(28.5%) in-hospital deaths. The prevalence of chronic disease in women and men was 66.3 and 68.5%, respectively,
while that of obesity was 12.9 and 11.1%, respectively. Association of obesity and chronic disease status varied by
age (p < 0.001). Under 50 years of age, obesity and chronic disease were associated with in-hospital mortality within
28 days of admission in a dose-response manner, such that patients with both obesity and chronic disease had the
highest risk with a hazard ratio (HR) of in-hospital mortality of 2.99 (95% CI: 2.12, 4.21) in men and 2.16 (1.42, 3.26)
in women compared to patients without obesity or chronic disease. Between the ages of 50–69 years, obesity and
chronic disease remained associated with in-hospital COVID-19 mortality, but survival in those with obesity was
similar to those with and without prevalent chronic disease. Beyond the age of 70 years in men and 80 years in
women there was no meaningful difference between those with and without obesity and/or chronic disease.
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Conclusion: Obesity and chronic disease are important risk factors for in-hospital mortality in younger age groups,
with the combination of chronic disease and obesity being particularly important in those under 50 years of age.
These findings have implications for targeted public health interventions, vaccination strategies and in-hospital
clinical decision making.
Keywords: Obesity, Chronic disease, Ageing, COVID-19
Introduction
The severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), which causes coronavirus disease-2019
(COVID-19), is devastating global economies and put-
ting unprecedented strain on health care services. The
mortality and economic burden caused by the virus have
precipitated an unparalleled global research response [1],
including efforts to identify people at greatest risk of de-
veloping severe illness or mortality. Age, sex, chronic
disease and obesity have emerged as key risk factors
within large population level cohorts [2, 3]. Overweight
and obesity have been suggested to increase the risk of
severe disease or mortality by a factor of two [4], with
diabetes, hypertension, coronary heart disease, chronic
kidney disease, respiratory disease, and cancer all being
shown to be associated with the risk of adverse COVID-
19 outcomes [5–8]. However, whilst these factors have
been extensively investigated individually, their interac-
tions are less well understood. It is unknown, for ex-
ample, whether obesity remains a strong risk factor in
those without chronic disease, or whether the combin-
ation of obesity with chronic disease increases the risk,
given their common coexistence. Whilst studies investi-
gating the associations of obesity and chronic disease
with COVID-19 outcomes have been adjusted for age,
sex or both, adjustment can render invisible heterogen-
eity in associations across strata of interest which can
mask important differences, including within COVID-
19 research [9]. Early preliminary research in small co-
horts has started to demonstrate the presence of het-
erogeneity for age, with obesity found to be more
prevalent or a stronger risk factor for COVID-19 out-
comes in younger compared to older populations
[10–14], suggesting that younger people with obesity
may be a priority group for public health testing and
preventative strategies. However, not all research has
supported these findings [15] and it is unknown
whether age modifies associations between obesity and
COVID-19 mortality equally in men and women or
how obesity combines with associations of chronic dis-
ease. Examining how age modifies associations of com-
binations of common risk factors with COVID-19
outcomes will allow for more nuance and personalisa-
tion in risk communication, public health strategies and
clinical decision making.
We use the ISARIC CCP-UK database to investigate
associations between obesity, chronic disease and their
combination with in-hospital death in patients admitted
with COVID-19 and whether these associations are
modified by age in men and women.
Methods
Study population
This study uses data from the Clinical Characterisation
Protocol UK (CCP-UK) for Severe Emerging Infection
developed by the International Severe Acute Respiratory
and emerging Infections Consortium (ISARIC) and the
World Health Organisation in response to the A/
H1N1pdm2009 influenza pandemic [16]. ISARIC CCP-
UK was reactivated in the UK on 17th January 2020 as
the scale of the COVID-19 pandemic started to emerge.
Data was collected from 260 hospitals in England,
Scotland, and Wales. The protocol, amendment history,
case report form, information leaflets, consent forms,
and detail of the Independent Data and Material Access
Committee (IDAMAC) are available at https://isaric4c.
net. The study was approved by the South Central - Ox-
ford C Research Ethics Committee in England (Ref: 13/
SC/0149), and by the Scotland Research Ethics Commit-
tee (Ref: 20/SS/0028). For this study, we included those
with a coding of “Proven or high likelihood of infection
with a pathogen of Public Health Interest” reflecting that
a preparedness protocol cannot assume a diagnostic test
will be available for an emergent pathogen. Site training
also emphasised importance of only recruiting proven
cases of COVID-19. Additional inclusion criteria were: a
hospital admittance date from the start of the COVID-
19 pandemic in the UK (6th February 2020) with a
complete follow-up coding indicating discharge, in-
hospital death, or remaining in hospital. We excluded
patients coded as having had a solid organ transplant or
people with rare diseases and inborn errors of metabol-
ism that significantly increase the risk of infections (such
as severe combined immunodeficiency (SCID) or homo-
zygous sickle cell). Data were available up until 12th Oc-
tober 2020. Of the 76,327 individuals within this dataset,
62,689 (82%) had a valid censoring date with complete
data for age, sex, obesity and chronic disease (diabetes,
chronic heart disease, hypertension, chronic kidney
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disease, chronic pulmonary disease or cancer) and were
included in this analysis.
Data collection
Data collection was undertaken by research nurses, ad-
ministrators and medical students. Detailed admission
data were collected on day 1 with follow-up data on
disease progression collected on day 3, 6, and 9, and on
discharge, death or continued hospitalisation beyond 28
days. Discharge was further coded as discharged alive,
discharged to palliative care, or discharged to another
facility.
Obesity was coded as yes/no on assessment from the
attending clinician. Clinical assessment was based on ob-
jective measurement of obesity, such as by calculation of
the body mass index (≥ BMI of 30 kg/m2), measurement
of abdominal girth or on clinical judgment.
Chronic disease was based on clinician diagnosed sta-
tus. In this study, we included diseases that have been
consistently associated with COVID-19 outcomes [5–8]:
chronic cardiac disease (coronary artery disease, heart
failure, congenital heart disease, cardiomyopathy,
rheumatic heart disease), hypertension, chronic kidney
disease (diagnosed chronic kidney disease or estimated
glomerular filtration rate < 60mL/min/1.73m2), chronic
pulmonary disease (chronic obstructive pulmonary dis-
ease [chronic bronchitis, emphysema], cystic fibrosis,
bronchiectasis, interstitial lung disease, pre-existing re-
quirement for long term oxygen therapy), diabetes (type
1 or 2), and malignant neoplasm (current solid organ or
haematological malignancy).
Outcome
The main outcome was in-hospital mortality coded as
“death” for the patient outcome following hospital ad-
mittance. In order to avoid those with prolonged hos-
pital stay biasing results, outcomes were censored at 28-
days.
Statistical analysis
The main analysis used a stratified rather than an ad-
justed model to investigate heterogeneity across strata.
Data were stratified by age (< 50 years, 50–59 years, 60–
69 years, 70–79 years, ≥80 years) and sex. Obesity and
chronic disease were categorised into four mutually ex-
clusive categories of interest: 1) non-obese without
chronic disease, 2) obese without chronic disease, 3)
non-obese with chronic disease, 4) obese with chronic
disease. The Kaplan–Meier survival function was used to
plot survival and generate survival tables. The log-rank
test was used to determine overall differences in survival
rates between obesity and chronic disease categories.
Cox proportional hazards models were further used to
quantify the relative hazard by age and sex strata for
each combination of obesity and chronic disease com-
pared to patients with no obesity and no chronic disease.
In order to formally test whether age modified associa-
tions, an interaction test for age category by obesity/
chronic disease category was also analysed, separately in
men and women.
Two sensitivity analyses were conducted. The first
considered the potential for discharge to palliative care
biasing results, particularly in older individuals, by re-
peating analysis for a composite outcome of in-hospital
mortality or discharge to palliative care. The second sen-
sitivity analysis included obesity and each chronic dis-
ease separately to confirm whether the overall pattern of
association observed in the main analysis was consistent
for each individual disease and obesity. All analysis was
conducted in SPSS (v26). P < 0.05 was used to denote
significance for main effects and interactions. Data are
reported as mean (95% CI), unless reported otherwise.
Results
Table 1 shows the age, chronic disease and obesity char-
acteristics of the included cohort. The analysis included
27,624 women and 35,065 men, with 6407 (23.2%) and
10,001 (28.5%) in-hospital deaths, respectively. The me-
dian number of days until discharge or death was be-
tween 8 and 9 days for both men and women. The
proportion of patients with at least one chronic disease
was 66.3 and 68.5% in women and men, respectively,
while the prevalence of obesity was 12.9 and 11.1%, re-
spectively. Rates of chronic disease and obesity by age
group are shown in Supplementary Table S1, with rates
of chronic disease highest in those over 80 years of age
(83.6%) and rates of obesity highest in those 50–59 years
of age (20.5%) and lowest in those over 80 years of age
(4.7%).
Figure 1 for men and Fig. 2 for women show the 28-
day survival across obesity, chronic disease and age cat-
egories, with Fig. 3 showing the accompanying hazard
ratios (data shown in Supplementary Table S2). Associa-
tions between obesity and chronic disease categories
with in-hospital mortality varied by age in men and
women (P < 0.001 for interaction).
For patients under 50 years of age, obesity and chronic
diseases were associated with in-hospital mortality in a
dose-response manner, such that those with both obesity
and chronic disease had the lowest survival (Figs. 1 and
2), with a HR of 2.99 (95% CI: 2.12, 4.21) in men and
2.16 (1.42, 3.26) in women compared to patients without
obesity or chronic diseases (Fig. 3). In the age categories
of 50–59 and 60–69 years, obesity and chronic disease
remained associated with in-hospital COVID-19 mortal-
ity, but survival in those with obesity tended to be simi-
lar in those with and without coexisting chronic disease
(Fig. 3). For example, in women between 50 and 59
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years, compared to those without obesity or chronic dis-
ease, the HR of in-hospital mortality in those with obes-
ity without chronic disease was 2.61 (1.78, 3.82) while
the HR in those with obesity and chronic disease was
2.12 (1.52, 2.93). Between 70 and 79 years, there was no
clear pattern of association between obesity and chronic
disease in men, whereas risk in those with obesity and
chronic disease remained moderately elevated in women
(HR = 1.33; 1.10, 1.60) (Fig. 3). Beyond 80 years of age,
survival was low across all categories of obesity and
chronic disease status (Figs. 1 and 2) with no meaningful
difference in survival between those without obesity and
chronic disease compared to those with obesity and/or
chronic disease in men and women.
The strength and pattern of association was un-
changed when those discharged to palliative care (men =
437, women = 459) were included in a composite
outcome with mortality (Supplementary Figure S1). The
pattern of association with in-hospital mortality was also
consistent across categories of age when obesity and
each included chronic disease were analysed individually
(Supplementary Figure S2), with associations weakest in
older adults.
Discussion
In patients admitted to hospital with COVID-19, mutu-
ally exclusive categories of obesity and chronic disease
are consistently associated with in-hospital mortality in
younger adults but not in those 70 years of age or over
for men or 80 years and over for women. In men and
women under 50 years of age, obesity and the coexist-
ence of chronic diseases combined to increase the risk of
in-hospital mortality by between 2 to 3 times compared
to those without obesity or chronic diseases. Between
the ages of 50 to 69 years, obesity and chronic diseases
remained associated with a higher risk of in-hospital
mortality in men and women, but their combination did
not appear to further reduce survival beyond having
Table 1 Participant characteristics stratified by sex
Categorical Variables Men (n = 35,065) Women (27,624)
Number Column % Number Column %
Age Category
< 50 years 5398 15.4 4586 16.6
50–59 years 4408 12.6 2745 9.9
60–69 years 5789 16.5 3587 13.0
70–79 years 8187 23.3 5581 20.2
80 years 11,283 32.2 11,125 40.3
Hypertension 9756 46.4 8234 46.3
Chronic Heart Disease 11,491 33.2 7651 28.1
Diabetes 8379 24.8 5364 20.1
Chronic pulmonary disease 5985 17.3 4449 16.3
Chronic Kidney Disease 5553 16.0 4583 16.8
Cancer 4197 12.1 3161 11.6
Any chronic disease 24,007 68.5 18,316 66.3
Obesity 3901 11.1 3561 12.9
Mutually exclusive categories of obesity and chronic disease
Non obese, no chronic disease 10,103 28.8 8259 29.9
Obese, no chronic disease 955 2.7 1049 3.8
Non-obese, with chronic disease 21,061 60.1 15,804 57.2
Obese with chronic disease 2946 8.4 2512 9.1
In-hospital mortality within 28 days 10,001 28.5 6407 23.2
Discharged within 28 days 20,388 58.1 17,625 63.8
Remain in hospital after 28 days 4676 13.3 3592 13.0
Continuous Variables Median 25th percentile 75th percentile Median 25th percentile 75th percentile
Days in hospital until death 9 4 16 8 4 16
Days in hospital until discharge 8 4 16 8 4 16
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Fig. 1 28-day survival in men across mutually exclusive categories of obesity and chronic disease by age
Fig. 2 28-day survival in women across mutually exclusive categories of obesity and chronic disease by age
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obesity only. In those aged 70 years or over in men and
80 or over years in women, survival was low across all
combinations of obesity and chronic disease, but was
not meaningfully further lowered in those with obesity
and/or chronic disease.
Whilst obesity and chronic disease have been estab-
lished as risk factors for SARS-CoV-2 infection, severe
disease and mortality [2–8], there has been less focus on
establishing how these risk factors combine in men and
women and whether the pattern of association is con-
sistent across different age groups. This study expands
preliminary findings from smaller cohorts suggesting
obesity may be a particularly important risk factor in
younger ages. Among 7606 patients in the United States,
associations of BMI with in-hospital mortality and
mechanical ventilation were strongest in those under 50
years and largely attenuated in those over 70 years [14],
which was consistent with an early study from a New
York hospital system [10]. Another study from the USA
found that in 6916 persons testing positive for COVID-
19, obesity was more strongly associated with mortality
in younger age men [12], while a study from Spain in-
volving 1105 persons hospitalised with COVID-19 also
reported that obesity was more strongly associated with
admission in younger adults [13]. However, a study in-
volving 5795 persons admitted to hospitals in Paris with
COVID-19 suggested obesity was similarly associated
with mortality across age groups [15], although uncer-
tainty around the estimates of risk were high due to a
low number of events when stratified by age. The
present study suggests that, with cases of COVID-19
that are severe enough to warrant admission to hospital,
the coexistence of obesity and chronic disease substan-
tially reduces survival in those under 50 years of age,
with obesity remaining a risk factor with or without the
coexistence of chronic disease up until the age of 70
years. However, beyond this age, obesity with or without
chronic disease may not meaningfully affect the already
low levels of survival associated with older age, particu-
larly in men. These findings broadly support the vaccin-
ation strategy within the United Kingdom [17], the first
country to approve the roll-out of a COVID-19 vaccine.
The strategy sets out health care workers and older
adults (with priority set in descending age order until
≥65 years) as the first priority, followed by those over 16
years of age with an underlying health condition, includ-
ing morbid obesity and the chronic diseases included in
this paper.
Strengths of this analysis include the large multisite
sample with data collected from trained staff according
to standard operating procedures. In the United
Kingdom (UK), there were a total of 151,641 hospital ad-
missions with COVID-19 up until October 12th (https://
coronavirus.data.gov.uk/). Therefore, our cohort repre-
sents 41% of all UK hospital admissions in the period
covered by this study. This large sample size allowed for
stratification by age, sex and mutually exclusive categor-
ies of obesity and chronic diseases, allowing survival esti-
mates for each strata rather than relying on adjusted
estimates which can mask important differences between
groups. However, there are some limitations. Namely,
the large sample size was only made possible by relying
on clinical records: for example, obesity was defined by a
clinician assessment. Therefore, the prevalence of obesity
appears an under-estimate compared to levels that
would have been expected based on population level es-
timates [18]. It is likely the coding of obesity in this
study therefore reflects more extreme phenotypes of
obesity likely to prompt a clinical coding. Other factors
like age may also influence whether patients were
assessed for obesity, which could act to bias the reported
associations. Nevertheless, in order to inform clinical
Fig. 3 Risk of in-hospital mortality in men and women across mutually exclusive categories of obesity and chronic disease by age
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care, analysed risk factors need to reflect data that is read-
ily available to treating clinical staff through clinical re-
cords. Therefore, the coding of obesity in this study may
have real world utility as it corresponds to data coded
within routine clinical care. Another potential limitation is
that this study is specific to in-hospital mortality and does
not include COVID-19 mortality events in the commu-
nity. Post-acute COVID-19 discharge from hospital of pa-
tients into palliative care is increasingly recognised with
‘long-COVID-19’ [19], which may have acted to bias find-
ings through longer-term hospital admissions followed by
a high mortality risk once discharged. Nevertheless, asso-
ciations were unchanged when patients discharged into
palliative care were included within the outcome as a
composite with mortality.
In conclusion, this study suggests obesity and chronic dis-
eases act as important risk factors for lower in-hospital sur-
vival in younger age groups, with the combination of
chronic disease and obesity being a particularly important
risk factor in patients under 50 years of age. Associations
appeared to be attenuated with age, such that obesity and
chronic diseases had little impact on survival in men be-
yond 70 years and women beyond 80 years. These findings
suggests that younger adults with obesity and pre-existing
chronic disease may need to be targeted by public health
interventions to reduce the risk of transmission or to en-
gage with vaccination programmes. However, obesity and
chronic disease may be less important or informative for
clinical decision making in the treatment of COVID-19 for
older adults, where other factors may be more relevant.
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